Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer

University Hospital, Toulouse35 enrolled

Overview

Pancreatic cancer represents the fourth cause of death by cancer in western countries. The only curative treatment is surgery but this one is possible only in 10 to 15 % of cases. To date, there are few biomarkers in circulating blood as prognostic or diagnostic markers in pancreatic cancer. The purpose of this study is to determine if the pancreatic tumor mobilization during its resection impacts the quantity of circulating tumor DNA in peripheral and portal blood.

The investigators will analyze if the tumor mobilization increases circulating DNA rate in peripheral and portal blood. Moreover, circulating tumor DNA will be measured during 12 months after surgery in peripheral blood. They will use a gene mutation detection technique called Next Generation Sequencing (NGS) which is more specific than a simple Polymerase Chain Reaction (PCR).

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Resectable Pancreatic Cancer

Interventions

Blood samplesOTHER

Blood samples will be taken to analyze the circulating tumor DNA rate by NGS

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Every patient taken care by Toulouse University Hospital for the resection of a non-metastatic pancreatic adenocarcinoma by whipple resection. * Patient aged over 18 years old * Patient having given his written consent * Patient with social insurance coverage Exclusion Criteria: * Patients who had surgery, but their pathological examination of the resected specimen does not contain adenocarcinoma. * Patient for whom the surgery was not realized (exploratory laparotomy)

Locations (1)

University Hospital

Toulouse, France

Outcomes

Primary Outcomes

Kinetic of circulating tumor DNA evaluation in resected pancreatic cancer.

To analyse circulating tumor DNA rate in the portal vein and in peripheral blood at various times of pancreatic cancer resection. Kinetic to 1 day before surgery, during surgery and after surgery (1 day, 10days , one month, 3 months, 6 months and one year after surgery)

Time frame: Kinetic up to one year

Secondary Outcomes

Overall survival

to analyse correlation between circulating tumor DNA rate and overall survival and survival without recurrence. Kinetic to 1 day before surgery, during surgery and after surgery (1 day, one month, 3 months, 6 months and one year after surgery)

Time frame: Kinetic up to one year

Correlation between circulating tumor DNA rate and Ca19.9 dosage

to analyse correlation between circulating tumor DNA and Ca19.9 rate after dosage of C19.9. Kinetic to 1 day before surgery, and after surgery (on day, one month, 3 months, 6 months and one year after surgery)

Time frame: Kinetic up to one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.